Comparison of CSF biomarkers in multiple sclerosis patients treated with natalizumab and rituximab
Background: Patients with relapsing remitting multiple sclerosis (RRMS) treated with the high-efficacy drugs natalizumab (NTZ) or rituximab (RTX) generally show no evidence of disease activity. Currently, there is no head-to-head comparison between NTZ and RTX of neurodegenerative and neuroinflammatory biomarkers in cerebrospinal fluid (CSF). Objectives: To compare CSF biomarkers in a stable RRMS
